Pediatric Obesity Clinic and Wellness Unit, General Hospital of Mexico, Mexico City 06720, Mexico.
Unidad de Vinculación de la Facultad de Medicina, UNAM, Instituto Nacional de Medicina Genómica, Mexico City 14610, Mexico.
Medicina (Kaunas). 2023 Oct 7;59(10):1785. doi: 10.3390/medicina59101785.
: Metabolic-dysfunction-associated steatotic liver disease or MASLD is the main cause of chronic liver diseases in children, and it is estimated to affect 35% of children living with obesity. This study aimed to identify metabolic phenotypes associated with two advanced stages of MASLD (hepatic steatosis and hepatic steatosis plus fibrosis) in Mexican children with obesity. : This is a cross-sectional analysis derived from a randomized clinical trial conducted in children and adolescents with obesity aged 8 to 16 years. Anthropometric and biochemical data were measured, and targeted metabolomic analyses were carried out using mass spectrometry. Liver steatosis and fibrosis were estimated using transient elastography (Fibroscan Echosens, Paris, France). Three groups were studied: a non-MASLD group, an MASLD group, and a group for MASLD + fibrosis. A partial least squares discriminant analysis (PLS-DA) was performed to identify the discrimination between the study groups and to visualize the differences between their heatmaps; also, Variable Importance Projection (VIP) plots were graphed. A VIP score of >1.5 was considered to establish the importance of metabolites and biochemical parameters that characterized each group. Logistic regression models were constructed considering VIP scores of >1.5, and the receiver operating characteristic (ROC) curves were estimated to evaluate different combinations of variables. : The metabolic MASLD phenotype was associated with increased concentrations of ALT and decreased arginine, glycine, and acylcarnitine (AC) AC5:1, while MASLD + fibrosis, an advanced stage of MASLD, was associated with a phenotype characterized by increased concentrations of ALT, proline, and alanine and a decreased Matsuda Index. : The metabolic MASLD phenotype changes as this metabolic dysfunction progresses. Understanding metabolic disturbances in MASLD would allow for early identification and the development of intervention strategies focused on limiting the progression of liver damage in children and adolescents.
代谢功能障碍相关脂肪性肝病或 MASLD 是儿童慢性肝病的主要原因,据估计,肥胖儿童中有 35%患有这种疾病。本研究旨在确定与 MASLD 的两个晚期阶段(肝脂肪变性和肝脂肪变性伴纤维化)相关的代谢表型,研究对象为墨西哥肥胖儿童。
这是一项横断面分析,源自一项针对 8 至 16 岁肥胖儿童和青少年的随机临床试验。测量了人体测量学和生化数据,并使用质谱进行了靶向代谢组学分析。使用瞬态弹性成像(法国巴黎 Fibroscan Echosens)评估肝脂肪变性和纤维化。研究了三组:非 MASLD 组、MASLD 组和 MASLD +纤维化组。进行了偏最小二乘判别分析(PLS-DA),以确定研究组之间的区别,并可视化它们的热图之间的差异;还绘制了变量重要性投影(VIP)图。VIP 得分>1.5 被认为是确定代谢物和生化参数对每个组特征重要性的标准。考虑 VIP 得分>1.5 构建了逻辑回归模型,并估计了接收者操作特征(ROC)曲线,以评估不同变量组合的效果。
MASLD 的代谢表型与 ALT 浓度升高和精氨酸、甘氨酸和酰基辅酶 A(AC)AC5:1 降低有关,而 MASLD +纤维化,即 MASLD 的晚期阶段,与 ALT、脯氨酸和丙氨酸浓度升高以及 Matsuda 指数降低有关的表型有关。
随着代谢功能障碍的进展,代谢性 MASLD 表型会发生变化。了解 MASLD 中的代谢紊乱可以实现早期识别,并制定干预策略,重点限制儿童和青少年肝损伤的进展。